Becton Dickinson (NYSE:BDX) said today that it has stopped selling a point-of-care test touted as being able to detect antibodies to COVID-19 in as little as 15 minutes. The test, by BioMedomics, was one of about 100 serological tests that the FDA allowed manufacturers to sell beginning March 26, 2020, if the companies self-validated their accuracy. […]
BioMedomics
BD to launch point-of-care COVID-19 antibody test
Becton Dickinson (NYSE:BDX) yesterday announced a new point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19 in as little as 15 minutes. The new test, developed and manufactured by BioMedomics (Morrisville, N.C.), will be available through BD and distributed exclusively by Henry Schein (NSDQ:HSIC) to healthcare providers throughout the […]